泰華天(tian)然生(sheng)物(wu)制藥有限公司成立于1993年,是一(yi)家集藥源種(zhong)植基地、原料藥和(he)中(zhong)成藥的生(sheng)產(chan)、銷售為一(yi)體的現(xian)代化高(gao)新(xin)制藥企業。公司生(sheng)產(chan)基地位于素有“天(tian)然藥物(wu)寶(bao)庫”之稱(cheng)的秦(qin)嶺南(nan)麓陜西省商洛市洛南(nan)縣,總用(yong)地面積兩(liang)萬余平(ping)米(mi)。
公(gong)司(si)現設有藥(yao)源種(zhong)(zhong)(zhong)植(zhi)基地(di)(di)(di)、生產基地(di)(di)(di)、中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)(cheng)藥(yao)營(ying)銷(xiao)中(zhong)(zhong)(zhong)(zhong)(zhong)心、原(yuan)料藥(yao)海(hai)外(wai)營(ying)銷(xiao)中(zhong)(zhong)(zhong)(zhong)(zhong)心四個事業部,生產藥(yao)品(pin)涵蓋了腫瘤科(ke)、消化科(ke)、婦科(ke)、皮(pi)膚科(ke)等(deng)(deng)(deng)多個領域。原(yuan)料藥(yao)海(hai)外(wai)營(ying)銷(xiao)中(zhong)(zhong)(zhong)(zhong)(zhong)心以高三尖杉(shan)(shan)酯堿(jian)、紫(zi)杉(shan)(shan)醇等(deng)(deng)(deng)抗(kang)腫瘤原(yuan)料藥(yao)為核心,產品(pin)主(zhu)要銷(xiao)往(wang)歐盟、以色列、俄羅斯、韓(han)國(guo)等(deng)(deng)(deng)發達國(guo)家(jia)和地(di)(di)(di)區,受到境外(wai)客(ke)戶(hu)的(de)(de)高度贊譽和支持;中(zhong)(zhong)(zhong)(zhong)(zhong)成(cheng)(cheng)藥(yao)營(ying)銷(xiao)中(zhong)(zhong)(zhong)(zhong)(zhong)心以便通片、芪棗(zao)顆粒、棗(zao)仁(ren)安神顆粒、杜(du)仲平壓片等(deng)(deng)(deng)內科(ke)用(yong)藥(yao)為龍頭,銷(xiao)售網絡覆蓋全國(guo)各個省份,并且獲得廣大(da)患者的(de)(de)一致好評和信(xin)賴(lai);藥(yao)源種(zhong)(zhong)(zhong)植(zhi)基地(di)(di)(di)主(zhu)要負(fu)責公(gong)司(si)自有產品(pin)原(yuan)藥(yao)材(cai)基地(di)(di)(di)建設與供(gong)給,現有原(yuan)料藥(yao)種(zhong)(zhong)(zhong)植(zhi)基地(di)(di)(di)3000余畝,主(zhu)要植(zhi)株為曼(man)迪亞(ya)紅豆杉(shan)(shan)和中(zhong)(zhong)(zhong)(zhong)(zhong)國(guo)粗榧,為公(gong)司(si)原(yuan)料藥(yao)紫(zi)杉(shan)(shan)醇和高三尖杉(shan)(shan)酯堿(jian)提供(gong)了優質(zhi)的(de)(de)天(tian)然(ran)原(yuan)料,同(tong)時(shi)科(ke)學利用(yong)土地(di)(di)(di)資(zi)源,在(zai)基地(di)(di)(di)共(gong)種(zhong)(zhong)(zhong)植(zhi)連翹、杜(du)仲、苦參等(deng)(deng)(deng)藥(yao)材(cai)數十萬(wan)株。除(chu)此之(zhi)外(wai),公(gong)司(si)在(zai)秦嶺儲備林(lin)地(di)(di)(di)一萬(wan)余畝,并逐步(bu)推進中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)材(cai)生態種(zhong)(zhong)(zhong)植(zhi)和野生撫育計劃,在(zai)加強中(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)材(cai)道(dao)地(di)(di)(di)產區環境保護(hu)的(de)(de)同(tong)時(shi),為大(da)家(jia)提供(gong)療效更為突(tu)出的(de)(de)優質(zhi)天(tian)然(ran)藥(yao)材(cai)。
公司生(sheng)產線(xian)已全部(bu)通(tong)過國(guo)家(jia)新版GMP認證(zheng),中(zhong)藥(yao)飲片、配方顆粒、保健食品事業部(bu)已處于籌建中(zhong),預計(ji)2020年(nian)將(jiang)實現(xian)各個板塊的投產。公司還(huan)將(jiang)在傳(chuan)統的原料藥(yao)和(he)中(zhong)成藥(yao)基礎上,加大藥(yao)物(wu)的科研(yan)(yan)力度,并從植(zhi)物(wu)單體(ti)開發(fa)、化學(xue)(xue)藥(yao)物(wu)合成及成藥(yao)衍生(sheng)物(wu)的科學(xue)(xue)研(yan)(yan)發(fa)做(zuo)出更(geng)多的努力。預計(ji)2025年(nian),泰華制藥(yao)將(jiang)實現(xian)以種植(zhi)、生(sheng)產、研(yan)(yan)發(fa)、銷售(shou)為一體(ti)的完整產業鏈覆蓋,屆(jie)時(shi)泰華醫藥(yao)健康產業將(jiang)發(fa)力,為社會和(he)患者提(ti)供更(geng)豐(feng)富的產品、更(geng)優質的服(fu)務。